Physician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry Disease

Summary

This program allows physicians to request permission from Amicus Therapeutics (Amicus) for treatment access to migalastat hydrochloride (HCl) for specific patients with Fabry disease. Treatment is open label.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications